As one of the first commercial partners to access the ReproUnion Biobank & Infertility Cohort (RUBIC), Caerus Biotech is collaborating with Rigshospitalet to analyze samples from 1000 men, using the company’s MiOXSYS system designed to measure oxidative stress in semen.
Male factor infertility accounts for nearly half of all fertility challenges and oxidative stress may be a key factor. Traditional diagnostic tools have been limited and MiOXSYS is addressing this gap by offering rapid, precise assessment of oxidative stress – an imbalance that can impair sperm function and reproductive outcomes.
“We see MiOXSYS as a tool that can transform male fertility care and potentially also be applied in other biological fluids relevant to fertility, such as follicular fluid and embryo culture media,” explains Martynas Linkevicius, Chief Commercial Officer at Caerus Biotech. “Our collaboration with Rigshospitalet gives us access to some of the most advanced fertility research in Europe, and importantly, the access to RUBIC samples in IVF models as well as data, which will also help us to strengthen the clinical evidence base for our technology.”
The collaboration with Rigshospitalet, led by Niels Jørgensen and Anja Pinborg, explores how MiOXSYS can contribute to a more nuanced understanding of male fertility and support IVF treatment strategies in general. Among the joint projects is also an investigation of optimal abstinence periods before sample collection – a parameter with significant clinical relevance.
“As we continue to collect more data in RUBIC we are also gearing up towards more collaborations with industry and this is a great example of how technology can be applied to both the biological samples and data. In this case RUBIC is a strong foundation to generate clinical data and a unique resource to analyze oxidative stress in the next 1000 of well-characterized samples,” says Niels Jørgensen.
As fertility rates continue to decline globally, tools like MiOXSYS offer a vital opportunity to improve diagnostics, personalize care, and support couples on their reproductive journeys.
“Our company advocates for more balanced and personalized fertility care that involves men earlier and more effectively in the process. So, we would like oxidative stress testing to be a routine part of male fertility assessment and complement current IVF practices,” concludes Martynas Linkevicius.
The MiOXSYS device provides results in under five minutes and has been in use across European markets since 2016. It was first developed in the U.S. and acquired by Caerus Biotech in 2021, who has offices in Lithuania, Switzerland and Austria.
